Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics (NASDAQ: FATE) announced a virtual event on August 19, 2021, to present interim Phase 1 clinical data for its FT596 and FT516 programs targeting relapsed/refractory B-cell lymphomas. The event will be accessible via the company’s website. Fate's iPSC product platform allows for the mass production of engineered cell therapies, enhancing treatment efficacy. FT516 is currently in trials as a standalone treatment for acute myeloid leukemia and in combination therapy, while FT596 targets B-cell antigens with promising preclinical results.

Fate Therapeutics (NASDAQ: FATE) has scheduled a conference call and live audio webcast for August 4, 2021, at 5:00 p.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. To participate, dial 800-773-2954 (toll-free) or 847-413-3731 (toll). The event will be accessible on the Company’s website under 'Events & Presentations.'

Fate Therapeutics is focused on developing programmed cellular immunotherapies for cancer, leveraging its proprietary iPSC product platform.

Fate Therapeutics (NASDAQ: FATE) appointed Mark Plavsic, DVM, PhD, RAC as its new Chief Technical Officer. Dr. Plavsic brings over 20 years of global biopharmaceutical experience, overseeing manufacturing and technical operations. His previous roles include CTO at Lysogene and SVP at Torque Therapeutics. The appointment supports Fate's expansion plans for its iPSC product platform and upcoming GMP manufacturing facility. As part of his employment, Dr. Plavsic received stock options and restricted stock units, indicating a commitment to the company's growth and innovation in engineered cell therapies.

Fate Therapeutics reported promising interim Phase 1 results for FT516, an off-the-shelf NK cell therapy for relapsed/refractory B-cell lymphoma, at the ASCO Annual Meeting. Out of 11 patients, 8 achieved an objective response, including 6 complete responses, with no serious adverse events or grade 3+ side effects noted. The ongoing study is currently enrolling in its fourth dose cohort. The favorable safety profile and activity signal potential for future indication-specific cohorts aimed at combining FT516 with CD20-targeted therapies.

Fate Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 1, 2021, at 1:00 p.m. ET, followed by the BofA Securities 2021 Napa Biopharma Virtual Conference on June 15, 2021, at 5:30 p.m. ET. Investors can access live webcasts on the company's website under the 'Events & Presentations' section. Fate Therapeutics focuses on developing innovative cellular immunotherapies using its proprietary iPSC platform.

Fate Therapeutics announced encouraging interim Phase 1 results for its off-the-shelf, iPSC-derived NK cell therapies, FT516 and FT538, in treating relapsed/refractory AML. Of 12 patients, 5 achieved complete leukemic blast clearance, with FT516 showing no dose-limiting toxicities or cytokine-related side effects. Notably, 2 patients from the second dose cohort maintained remission for over six months without further intervention. FT538 demonstrated anti-leukemic activity with one patient achieving a complete response. The studies indicate potential for durable treatments in outpatient settings.

Fate Therapeutics reported its Q1 2021 results, highlighting a strong cash position of $888.4 million following a $460 million public offering. Revenue reached $11.1 million, supported by collaborations with Janssen and Ono. The company plans to advance its FT538 program for solid tumors and will present Phase 1 data on FT516 and FT538 at an investor event on May 13. However, the PROTECT study for ProTmune did not meet its primary endpoint, leading to the discontinuation of its development.

Fate Therapeutics (NASDAQ: FATE) will host a conference call on May 5, 2021, at 5:00 p.m. ET to report its Q1 2021 financial results and provide a corporate update. Stakeholders can participate by calling toll-free at 800-708-4539 or toll at 847-619-6396, using confirmation number 50156207. The live audio webcast will be accessible on the company’s investor relations section of their website. Fate Therapeutics focuses on developing cellular immunotherapies for cancer, leveraging its proprietary iPSC product platform.

Fate Therapeutics announced that two oral and two digital presentations covering its iPSC-derived cancer immunotherapy pipeline will be featured at the 24th ASGCT Annual Meeting from May 11-14, 2021. Their FT516 and FT538 programs for treating relapsed/refractory acute myeloid leukemia (AML) will be highlighted during a virtual investor event on May 13. The ongoing clinical trials are investigating FT516 and FT538, aimed at enhancing NK cell activity against cancers, utilizing an innovative iPSC product platform.